cAMP-elevating agents such as adenosine and epinephrine (after binding to beta-adrenergic receptor) contribute to local vascular dilation and some of these dilations are endothelium-dependent. Previous intracellular Ca 2+ imaging studies in mouse microvessel endothelial cells reported that addition of adenosine or epinephrine induced a Ca2+ influx which is blocked by CNG channel blockers such as L-cis-diltiazem or LY83583. Inside-out patch clamp studies confirmed the existence of a cAMP-activated current in endothelial cells, strongly suggesting a functional role of CNG, in particular CNGA2, channels in endothelial cells. The current study went further to show that similar Ca2+ influx in response to adenosine or epinephrine occurred in endothelial cells in freshly isolated mouse aortic strips and was again blocked by L-cis-diltiazem. By measuring the isometric force developed in mouse aortic strips, we showed that CNGA2 channel-mediated Ca2+ influx in endothelial cells contributed to the endothelium-dependent vascular dilatation in response to adenosine and epinephrine. / In conclusion, cyclic nucleotides playa vital role in the regulation of intracellular Ca2+ concentration in vascular cells and Jurket T cells. / In Jurkat T cells, cyclic nucleotides regulated Ca2+ mobilization in a different way. Fluorescence-imaging studies showed that cGMP inhibited store-operated Ca2+ influx and histamine-induced Ca 2+ rise in Jurkat T cells through activation of PKG. / Thromboxane A2 (TxA2)-induced smooth muscle contraction has been implicated in cardiovascular, renal and respiratory diseases. This contraction can partly be attributed to TxA2-induced Ca2+ influx, which activates the Ca2+-calmodulin-MLCK pathway. This study aims to identify the channels that mediate TxA2-induced Ca2+ influx in vascular smooth muscle cells. Application of U-46619, a thromboxane A2 mimic, resulted in a constriction in endothelium-denuded small mesenteric artery segments. The constriction relied on the presence of extracellular Ca2+, because removal of extracellular Ca2+ abolished the constriction. This constriction was partially inhibited by a L-type Ca2+ channel inhibitor nifedipine (0.5-1 muM). The remaining component was inhibited by L-cis-diltiazem, a selective inhibitor for CNG channels, in a dose-dependent manner, Another CNG channel blocker LY83583 [6-(phenylamino)-5,8-quinolinedione] had similar effect. In primary cultured smooth muscle cells derived from rat aorta, application of U46619 (100 nM) induced a rise in cytosolic Ca2+, which was inhibited by L-cis-diltiazem. Immunoblot experiments confirmed the presence Of CNGA2 protein in vascular smooth muscle cells, These data suggest a functional role of CNG channels in U-46619-induced Ca 2+ influx and contraction of smooth muscle cells. / Leung, Yuk Ki. / "August 2010." / Adviser: Yao Xiaoxiang. / Source: Dissertation Abstracts International, Volume: 73-04, Section: B, page: . / Thesis (Ph.D.)--Chinese University of Hong Kong, 2011. / Includes bibliographical references (leaves 116-132). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [201-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese.

O efeito devastador da hipotensão na mortalidade relacionada ao trauma de crânio é bem estabelecido. Este estudo avalia a resposta hemodinâmica sistêmica e cerebral à reposição volêmica com Solução de Ringer Lactato (RL) ou Salina Hipertônica a 3% (SSH 3%), o comportamento da liberação de prostanóides encefálicos, aspectos anátomo-patológicos encefálicos e aspectos neurológicos, durante a fase aguda do choque hemorrágico (CH) associado ao traumatismo craniencefálico (TCE). MÉTODOS: Quinze cães foram distribuidos em três grupos (n=5, cada), após randomização, de acordo com o protocolo de reposição volêmica, realizada após TCE (fluido-percussão cerebral, 4 atm) e balão epidural para induzir hipertensão intracraniana (HIC) a 20-25 mmHg e CH, induzido por remoção sanguínea até pressão arterial média (PAM) de 40 mmHg em 5 minutos: grupo CH+TCE+HSS 3% (8ml/kg), CH+TCE+RL (16ml/kg) e grupo CH+TCE (controle, sem tratamento). Simulamos o tratamento durante a fase pré-hospitalar e hospitalar precoce. Os grupos tratados receberam infusão sanguínea para atingir hematócrito de 30%. As medidas incluiram volume sanguíneo removido, volume de cristalóide infundido para restabelecer PAM, PAM, índice cardíaco (IC), pressão intracraniana (PIC), pressão de perfusão cerebral (PPC), lactato sistêmico e cerebral, taxas de extração de oxigênio, concentração plasmática de tromboxane e prostaciclina. Avaliamos o padrão pupilar dos animais e realizamos análise anátomo-patológica dos encéfalos. RESULTADOS: A reposição volêmica com RL ou SSH 3% promoveu maior benefício hemodinâmico que o grupo controle sem tratamento. A pressão de perfusão cerebral foi maior que no grupo controle e similar entre os grupos tratados; entretanto, a infusão de SSH 3% foi associada com valores mais baixos de PIC durante a fase \"hospitalar precoce\" e com maior osmolaridade e concentração de sódio plasmático. Não houve diferença nos valores da concentração venosa cerebral de prostaciclina e tromboxane. Os encéfalos do grupo tratado com SSH 3% não demonstraram edema e os hipocampos dos cães do grupo controle se mostraram isquêmicos em relação ao grupo tratado com SSH 3%. A reversão pupilar após alteração pupilar estabelecida ocorreu mais precocemente no grupo tratado com SSH 3% que RL. CONCLUSÕES: No evento de um trauma de crânio grave e choque hemorrágico, o uso de SSH 3% ou o dobro do volume de RL promoveram benefícios hemodinâmicos sistêmicos e cerebrais. Entretanto, valores mais baixos de PIC foram observados após SSH 3%. / The devastating effects of hypotension on head-trauma-related mortality are well known. This study evaluates the systemic and cerebral hemodynamic responses to volume replacement with 3% hypertonic saline (HSS) or lactated Ringer\'s solution (LR), during the acute phase of hemorrhagic shock (HS) associated with traumatic brain injury (TBI). METHODS: Fifteen mongrel dogs were assigned to one of three groups (n=5, each) according to the volume replacement protocol, infused after TBI (brain fluid percussion, 4atm) and epidural balloon to an intracranial pressure (ICP) higher than 20 mm Hg and HS, induced by blood removal to a mean arterial pressure (MAP) of 40 mm Hg in 5 minutes: Group HS+TBI+HSS (8 mL/kg of 3% HSS), HS+TBI+LR (16 mL/kg LR) and Group HS+TBI (controls, no fluids). We simulated treatment during prehospital and early hospital admission. Groups HS+TBI+HSS and HS+TBI+LR received shed blood infusion to a target hematocrit of 30%. Measurements included shed blood volume, fluid volume infused to restore MAP, MAP, cardiac output, cerebral perfusion pressure, cerebral and systemic lactate, and oxygen extraction ratios, tromboxane and prostaciclin. We evaluated the dog\'s pupil pattern and the anatomopathological study of the brain. RESULTS: Fluid replacement with HSS or LR promoted major hemodynamic benefits over control animals without fluids. Cerebral perfusion pressure was higher than controls and similar between treated groups; however, HSS infusion was associated with lower ICP during the \"early hospital phase\" and a higher serum sodium and osmolarity. There were no differences between groups in cerebral venous concentration of tromboxane and prostaciclin. There was no edema in brains of HSS group, the hypocampi of control\'s group showed ischemia comparing to HSS group. The pupils reverted early in HSS than LR group. CONCLUSION: In the event of severe head trauma and hemorrhagic shock, the use of HSS and larger volumes of LR promote similar systemic and cerebral hemodynamic benefits. However, a lower ICP was observed after HSS 3% than after LR.

Ho, Kwok Wa. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2007. / Includes bibliographical references (leaves 60-65). / Abstracts in English and Chinese. / Chapter Chapter I / Chapter 1.1. --- Thromboxane A2 (TP) Receptors --- p.1 / Chapter 1.1.1. --- Gene structure of human TP receptors --- p.1 / Chapter 1.1.2. --- Isoforms of TP receptor --- p.1 / Chapter 1.1.3. --- Distribution and expression of TP receptors in human --- p.2 / Chapter 1.1.4. --- Signal transduction of TP receptors --- p.4 / Chapter 1.1.5. --- Major agonists of TP receptor in animals and humans --- p.7 / Chapter 1.1.5.1. --- Thromboxane A2 --- p.7 / Chapter 1.1.5.2. --- Prostaglandin H2 --- p.7 / Chapter 1.1.6. --- Functional studies: effect of TP receptor activation and blockade on vascular tone and atherosclerosis --- p.8 / Chapter 1.1.6.1. --- Effect of TP receptor activation --- p.8 / Chapter 1.1.6.1.1. --- On vaso-contraction --- p.8 / Chapter 1.1.6.1.2. --- On vaso-relaxation --- p.9 / Chapter 1.1.6.2. --- Effect of TP receptor blockade --- p.9 / Chapter 1.1.6.2.1. --- On endothelium dependent vaso-contraction --- p.9 / Chapter 1.1.6.2.2. --- On animal models related to atherosclerosis --- p.10 / Chapter 1.1.7. --- Objectives of current study --- p.10 / Chapter 1.2. --- Periadventitial Adipose (Fat) Tissue --- p.12 / Chapter 1.2.1. --- "General function, distribution and classification of fat" --- p.12 / Chapter 1.2.2. --- Representative endocrine/paracrine role of adipose tissues --- p.13 / Chapter 1.2.2.1. --- Leptin --- p.13 / Chapter 1.2.2.2. --- Angiotensinogen --- p.14 / Chapter 1.2.3. --- Functional studies on vessels with periadventital fat attached -The beginning of the story of adipcyte-derived relaxing factor (ADRF) --- p.15 / Chapter 1.2.3. --- Mechanisms behind the action of ADRF --- p.17 / Chapter 1.2.3.1. --- Nature of ADRF --- p.17 / Chapter 1.2.3.2. --- The mechanisms controlling the release of ADRF --- p.17 / Chapter 1.2.3.3. --- Proposed mechanisms explaining the anti-contractile effect mediated by ADRF --- p.17 / Chapter 1.2.4. --- Objectives of current study --- p.20 / Chapter Chapter II / Chapter 2.1. --- Tissue Preparation --- p.21 / Chapter 2.1.1. --- Preparation of blood vessels --- p.21 / Chapter 2.1.2. --- Procedures to remove the endothelium --- p.21 / Chapter 2.2. --- The Organ Bath Setups --- p.22 / Chapter 2.3. --- Calculation of Results --- p.24 / Chapter 2.3.1. --- Calculation of active tension --- p.24 / Chapter 2.3.2. --- Measurement of dry weight of arterial rings --- p.24 / Chapter 2.3.3. --- Measurement of the weight for periadventitial fat --- p.24 / Chapter 2.3.4. --- Statistic analysis --- p.24 / Chapter 2.4. --- Chemicals and Solutions --- p.25 / Chapter 2.4.1. --- Chemicals --- p.25 / Chapter 2.4.2. --- Solutions --- p.26 / Chapter Chapter III --- Stimulation of TP receptors by U46619 inhibits cGMP dependent vaso-relaxation --- p.27 / Chapter 3.1. --- Detail methods and materials --- p.27 / Chapter 3.1.1. --- "Safety announcement, tissue preparation and materials" --- p.27 / Chapter 3.1.1. --- Protocol --- p.27 / Chapter 3.1.1.1. --- PartI --- p.27 / Chapter 3.1.1.2. --- Part II --- p.28 / Chapter 3.1.1.3. --- Part III --- p.28 / Chapter 3.2. --- Results --- p.29 / Chapter 3.2.1. --- Effect of U46619 on vaso-relaxation --- p.29 / Chapter 3.2.2. --- Effect of Rho kinase and phosphodiesterase inhibitor on the inhibitory effect of U46619 --- p.29 / Chapter 3.2.3. --- The effect of low concentration of U46619 on vaso-relaxation --- p.29 / Chapter 3.3. --- Discussion --- p.37 / Chapter 3.3.1. --- Implication of the current study --- p.37 / Chapter 3.3.2. --- Formulated Theory --- p.41 / Chapter Chapter IV --- Effect of periadventitial fat on anti-relaxation effect induced by U46619 - A preliminary test --- p.43 / Chapter 4.1. --- Detail methods and materials --- p.43 / Chapter 4.1.1. --- "Safety announcement, tissue preparation and materials" --- p.43 / Chapter 4.1.2. --- Protocol --- p.43 / Chapter 4.1.2.1. --- Part I --- p.43 / Chapter 4.1.2.2. --- Part II --- p.44 / Chapter 4.1.2.3. --- Part III --- p.44 / Chapter 4.1.2.4. --- Part IV --- p.44 / Chapter 4.2. --- Results --- p.45 / Chapter 4.2.1. --- Effect of periadventitial fat on vaso-relaxation of rings contracted by phenylephrine --- p.45 / Chapter 4.2.2. --- Effect of periadventitial fat on vaso-relaxation of rings contracted by U46619 plus phenylephrine --- p.45 / Chapter 4.2.3. --- Effect of S18886 on vaso-relaxation in endothelium removed rings --- p.45 / Chapter 4.2.4. --- Effect of elevated extracellular potassium ions on vaso-relaxation --- p.46 / Chapter 4.3. --- Discussion --- p.56 / Chapter 4.3.1. --- Implication of current study --- p.56 / Chapter 4.3.2. --- Improvements and future perspectives of current study --- p.58 / Summary --- p.59 / References --- p.60

Introduction : L’effet biologique variable de l’aspirine a été attribué à un état de résistance pharmacologique. L’incidence de cette « résistance » varie selon la population ou la technologie étudiée. Méthodes : Nous avons déterminé la performance de 5 techniques évaluant l’effet de l’aspirine chez des sujets sains, non fumeurs et ne prenant aucune médication pouvant interférer avec la fonction plaquettaire. Des spécimens de sang et d’urine ont été obtenus avant et après 8-10 jours de prise de 80 mg d’aspirine. Résultats: Chez 45 sujets de 19-59 ans, la sensibilité (SE), la spécificité (SP), et la valeur optimale de coupure (CO) pour détecter l’effet de l’aspirine sont : agrégométrie par transmission optique induite avec 1,6 mM d’acide arachidonique (ATO-AA) - SE 100%, SP 95,9%, CO 20%; ATO-ADP 10 μM - SE 84,4%, SP 77,7%, CO 70%; VerifyNow® Aspirin - SE 100%, SP 95,6%, CO 550 ARU; agrégation en tube - SE 82,2%, SP 86,7%, CO 55%; TEG® - SE 82,9%, SP 75,8%, CO 90%; et le dosage de 11-dehydrothromboxane B2 urinaire - SE 62,2%, SP 82,2%, CO 60 pg/ml. Conclusions: La résistance à l’aspirine chez les sujets sains définie par ATO-AA et VerifyNow® Aspirin est rare. Puisque les autres techniques étudiées discriminent de façon sous optimale l’effet de l’aspirine, leur utilité dans la définition de la résistance pharmacologique à l’aspirine semble marginale. Ces résultats suggèrent qu’une proportion de la variabilité de l’incidence rapportée de “résistance à l’aspirine” est artefactuelle et reliée aux limitations technologiques de certaines analyses. / Background: Variable biological effect of aspirin is suggested to be related to pharmacological resistance. The incidence of this so-called “resistant” state varies with the study population and the assay used. Methods: We determined performance features of five assays used to assess aspirin effects in non smoking healthy volunteers not taking any drug known to interfere with platelet function. Blood and urine samples were obtained immediately before and after 8-10 days of aspirin 80 mg intake. Results: Forty-five participants 19-59 years old were enrolled. The sensitivity (SE), specificity (SP), and optimal cut-off (CO) value to detect the effect of aspirin were: light transmission aggregometry (LTA) with 1.6 mM arachidonic acid - SE 100%, SP 95.9%, CO 20%; LTA with ADP 10 μM - SE 84.4%, SP 77.7%, CO 70%; VerifyNow® Aspirin - SE 100%, SP 95.6%, CO 550 ARU; platelet count drop - SE 82.2%, SP 86.7%, CO 55%; TEG® - SE 82.9%, SP 75.8%, CO 90%; and urinary 11-dehydrothromboxane B2 levels - SE 62.2%, SP 82.2%, CO 60 pg/ml. Conclusions: Aspirin resistance in normal individuals as defined by arachidonic acid-induced LTA and the VerifyNow® assay is rare. Because the other assays discriminate suboptimally aspirin effect, they should not be used to define pharmacological “aspirin resistance”. These results suggest that a proportion of the variability in the reported incidence of aspirin resistance is artefactual and related to technical limitations of some assays.

No description available.

O efeito devastador da hipotensão na mortalidade relacionada ao trauma de crânio é bem estabelecido. Este estudo avalia a resposta hemodinâmica sistêmica e cerebral à reposição volêmica com Solução de Ringer Lactato (RL) ou Salina Hipertônica a 3% (SSH 3%), o comportamento da liberação de prostanóides encefálicos, aspectos anátomo-patológicos encefálicos e aspectos neurológicos, durante a fase aguda do choque hemorrágico (CH) associado ao traumatismo craniencefálico (TCE). MÉTODOS: Quinze cães foram distribuidos em três grupos (n=5, cada), após randomização, de acordo com o protocolo de reposição volêmica, realizada após TCE (fluido-percussão cerebral, 4 atm) e balão epidural para induzir hipertensão intracraniana (HIC) a 20-25 mmHg e CH, induzido por remoção sanguínea até pressão arterial média (PAM) de 40 mmHg em 5 minutos: grupo CH+TCE+HSS 3% (8ml/kg), CH+TCE+RL (16ml/kg) e grupo CH+TCE (controle, sem tratamento). Simulamos o tratamento durante a fase pré-hospitalar e hospitalar precoce. Os grupos tratados receberam infusão sanguínea para atingir hematócrito de 30%. As medidas incluiram volume sanguíneo removido, volume de cristalóide infundido para restabelecer PAM, PAM, índice cardíaco (IC), pressão intracraniana (PIC), pressão de perfusão cerebral (PPC), lactato sistêmico e cerebral, taxas de extração de oxigênio, concentração plasmática de tromboxane e prostaciclina. Avaliamos o padrão pupilar dos animais e realizamos análise anátomo-patológica dos encéfalos. RESULTADOS: A reposição volêmica com RL ou SSH 3% promoveu maior benefício hemodinâmico que o grupo controle sem tratamento. A pressão de perfusão cerebral foi maior que no grupo controle e similar entre os grupos tratados; entretanto, a infusão de SSH 3% foi associada com valores mais baixos de PIC durante a fase \"hospitalar precoce\" e com maior osmolaridade e concentração de sódio plasmático. Não houve diferença nos valores da concentração venosa cerebral de prostaciclina e tromboxane. Os encéfalos do grupo tratado com SSH 3% não demonstraram edema e os hipocampos dos cães do grupo controle se mostraram isquêmicos em relação ao grupo tratado com SSH 3%. A reversão pupilar após alteração pupilar estabelecida ocorreu mais precocemente no grupo tratado com SSH 3% que RL. CONCLUSÕES: No evento de um trauma de crânio grave e choque hemorrágico, o uso de SSH 3% ou o dobro do volume de RL promoveram benefícios hemodinâmicos sistêmicos e cerebrais. Entretanto, valores mais baixos de PIC foram observados após SSH 3%. / The devastating effects of hypotension on head-trauma-related mortality are well known. This study evaluates the systemic and cerebral hemodynamic responses to volume replacement with 3% hypertonic saline (HSS) or lactated Ringer\'s solution (LR), during the acute phase of hemorrhagic shock (HS) associated with traumatic brain injury (TBI). METHODS: Fifteen mongrel dogs were assigned to one of three groups (n=5, each) according to the volume replacement protocol, infused after TBI (brain fluid percussion, 4atm) and epidural balloon to an intracranial pressure (ICP) higher than 20 mm Hg and HS, induced by blood removal to a mean arterial pressure (MAP) of 40 mm Hg in 5 minutes: Group HS+TBI+HSS (8 mL/kg of 3% HSS), HS+TBI+LR (16 mL/kg LR) and Group HS+TBI (controls, no fluids). We simulated treatment during prehospital and early hospital admission. Groups HS+TBI+HSS and HS+TBI+LR received shed blood infusion to a target hematocrit of 30%. Measurements included shed blood volume, fluid volume infused to restore MAP, MAP, cardiac output, cerebral perfusion pressure, cerebral and systemic lactate, and oxygen extraction ratios, tromboxane and prostaciclin. We evaluated the dog\'s pupil pattern and the anatomopathological study of the brain. RESULTS: Fluid replacement with HSS or LR promoted major hemodynamic benefits over control animals without fluids. Cerebral perfusion pressure was higher than controls and similar between treated groups; however, HSS infusion was associated with lower ICP during the \"early hospital phase\" and a higher serum sodium and osmolarity. There were no differences between groups in cerebral venous concentration of tromboxane and prostaciclin. There was no edema in brains of HSS group, the hypocampi of control\'s group showed ischemia comparing to HSS group. The pupils reverted early in HSS than LR group. CONCLUSION: In the event of severe head trauma and hemorrhagic shock, the use of HSS and larger volumes of LR promote similar systemic and cerebral hemodynamic benefits. However, a lower ICP was observed after HSS 3% than after LR.

La migration cellulaire est un mécanisme important pour divers processus cellulaires tels que l’embryogenèse et la cicatrisation. De même, elle participe à des processus pathologiques notamment l’invasion des cellules malignes et la formation des métastases cancéreux. La dissémination métastatique est un processus très compliqué. L’acquisition du pouvoir migratoire invasif par la cellule maligne ainsi que son potentiel métastatique est gérée par le cytosquelette qui est dynamiquement modifié et contrôlé par des voies de signalisation intracellulaires. Cependant, la physiologie des cellules métastatiques et les cascades de signalisation qui les poussent à métastaser ne sont toujours pas comprises. Les protéines Ezrine, Radixine et Moésine (ERMs) jouent un rôle important dans l’organisation du cytosquelette au cortex cellulaire et elles sont des déterminantes clés de la migration cellulaire. Ainsi, une dérégulation à ce niveau peut conduire à une migration cellulaire aberrante. D’où l’implication des ERMs dans différents cancers agressifs et invasifs. Les ERMs sont régulées en aval de plusieurs acteurs cellulaires notamment les récepteurs membranaires. Plusieurs études ont rapporté que le récepteur au thromboxane A2 (RTXA2), un récepteur couplé à la protéine G (RCPG) favorise les métastases. Il a été décrit surtout dans le cadre de cancer du sein triple négatif (CSTN), l’un des cancers les plus mortels chez la femme. Les RCPG possèdent un rôle central dans presque toutes les fonctions physiologiques et constituent la plus grande famille des cibles médicamenteuses. D’une manière intéressante, les deux laboratoires de Dr Sébastien Carréno et Dr Michel Bouvier, ont découvert que le RTXA2 active les protéines ERMs à travers la GTPase RhoA. Dans ce projet de recherche on a identifié une nouvelle voie de signalisation liant le RTXA2 aux ERMs à travers la GTPase RhoA et la kinase SLK. Cette voie est impliquée dans la migration des cellules de cancer du sein triple négatif. Ainsi, on a pu démontrer que la moésine et la kinase SLK agissaient en aval du récepteur étudié pour favoriser la vitesse et la directionnalité de la migration des cellules de CSTN. 6 On a montré que la migration cellulaire dirigée en aval du RTXA2 est due à une polarité de la moésine au front de la migration. On a constaté aussi que la moésine est responsable d’une polarité des filaments d’actine au front de la migration suite à une activation du récepteur. Ce travail a mis en évidence une nouvelle cascade de signalisation importante pour la migration des cellules cancéreuses agressives triples négatives du sein ce que pourrait être une nouvelle cible des thérapies anti-métastatiques. / Cell migration is an important mechanism for various cellular processes such as embryogenesis and cicatrization. Likewise, it controls pathological processes including the invasion of malignant cells and the formation of metastases. Metastasis is a very complicated process. The acquisition of invasive migratory power by a malignant cell as well as its metastatic potential is regulated by the cytoskeleton which is dynamically modified and controlled by intracellular signaling pathways. However, metastatic cells physiology and the cascades causing their metastases are not clear yet. Ezrin, Radixin and Moesin (ERMs) proteins have an important role in organizing the cytoskeleton at the cell cortex and they are key determinants of cell motility. Thus, a deregulation at this point may lead to an aberrant cell migration. Hence, the involvement of ERMs in various aggressive and invasive cancers. ERMs are regulated downstream of several cellular actors in particular membrane receptors. Several studies have reported that the thromboxane A2 receptor (TXA2R), a G protein coupled receptor (GPCR) promotes metastasis. It has been described especially in the context of triple negative breast cancer (TNBC), one of the deadliest cancers in women. GPCR have a central role in almost all physiological functions and constitute the largest family of drug targets. Interestingly, the two laboratories of Dr Sébastien Carréno and Dr Michel Bouvier, have discovered that the TXA2R activates ERM proteins through the GTPase RhoA. In this research project, we have identified a new signaling pathway linking the TXA2 receptor to ERMs via RhoA and the kinase SLK. This pathway is involved in the migration of triple negative breast cancer cells. Thus, we demonstrated that moesin and SLK acted downstream of the receptor to promote the speed and directionality of TNBC cells migration. We discovered that the directed cell migration downstream of TXA2R is due to a polarization of moesin at the leading edge. We also observed that moesin is responsible for actin filaments polarity at the leading edge following an activation of the receptor. So, this work has revealed a new signaling cascade important for the migration of aggressive triple negative breast cancer cells which could be a new target for anti-metastatic therapies.

no / Human saphenous vein endothelial cells (HSVECs) derived from primary cultures of adult human veins constitute an excellent in vitro model for studying human endothelial metabolism. In this study we report the14C-labelled prostanoid profile of HSVECs under resting and stimulated conditions and the effect of the n-3 polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid on them. Results indicate that HSVECs while under resting conditions produce mainly prostaglandin F2 ¿(PGF2 ¿). After stimulation with calcium ionophore A23187, the cells were found to synthesise PGI2, PGE2and PGF2¿as major products and thromboxane B2and PGD2as minor products. Production of14C-labelled hydroxyeicosatetraenoic acids was not detected. Eicosapentaenoic acid was found to inhibit basal and stimulated prostanoid production whereas docosahexaenoic acid inhibited basal but strongly increased stimulated prostanoid production. These results may offer the basis for further studies aiming to investigate targets for pharmacological intervention in inflammatory conditions.

Au cours de la grossesse, une perfusion placentaire adéquate est indispensable au bon développement du fœtus. Dans certaines maladies comme la prééclampsie, celle-ci est altérée, compromettant ainsi la vie du fœtus, mais aussi celle de sa mère. Le retrait du placenta mène à la disparition des symptômes de la prééclampsie, suggérant un rôle central de ce dernier dans la maladie. Le placenta étant dépourvu d’innervation autonome, le tonus vasculaire placentaire doit être sous le contrôle de facteurs humoraux et tissulaires. Les vaisseaux placentaires sont très réactifs aux prostanoïdes. Le rapport thromboxane A2 (TXA2)/prostacycline (PGI2) est fortement augmenté dans les placentas de grossesses avec prééclampsie. De plus, le taux d’isoprostane, marqueur du stress oxydatif, est accru dans les placentas de femmes avec prééclampsie. Finalement, la prééclampsie s’accompagne d’un stress oxydatif placentaire marqué. Les espèces réactives de l’oxygène sont connues d’une part, pour oxyder l’acide arachidonique (AA), formant ainsi des isoprostanes et d’autre part, pour augmenter la production de TXA2 dans différents tissus, suite à l’activation des cyclooxygénases (COXs). Nous proposons que : 1. les prostanoïdes sont parmi les molécules endogènes qui contrôlent le tonus vasculaire placentaire. 2. la maladie modifie la réponse aux isoprostanes dans les vaisseaux placentaires. 3. l’induction d’un stress oxydatif placentaire entraîne une réponse vasoactive par activation de la voie du métabolisme de l’AA. Nous avons tout d’abord montré, dans des placentas obtenus de grossesses normotensives, que l’U-46619, un mimétique de la TXA2, de même que l’isoprostane, 8-iso-prostaglandine E2 (8-isoPGE2), ont augmenté fortement la pression de perfusion dans les cotylédons perfusés in vitro et la tension dans les anneaux d’artères chorioniques suspendus dans des bains à organe isolé. En revanche, dans les artères chorioniques de placentas obtenus de grossesses avec prééclampsie, ces réponses étaient modifiées puisque la réponse maximale à l’U-46619 était augmentée et celle à la 8-isoPGE2 diminuée. D’autre part, nous avons montré que les réponses maximales aux deux prostanoïdes étaient augmentées dans les vaisseaux placentaires de grossesse normale ou avec prééclampsie issus d’une délivrance prématurée par rapport à ceux d’une délivrance à terme. Ceci suggère une évolution de la réactivité des artères placentaires au cours du 3e trimestre de grossesse. En outre, les vaisseaux placentaires ont répondu aux prostanoïdes de façon semblable qu’ils aient été issus d’un accouchement vaginal ou d’une césarienne élective. Ceci indique que les prostanoïdes placentaires n’interviennent pas dans le processus de délivrance. D’un autre côté, l’utilisation de bloqueurs spécifiques des récepteurs TP à la TXA2, le SQ29,548 et l’ICI192,605, et des récepteurs EP à la prostaglandine E2, l’AH6809, nous ont permis de mettre en évidence le fait que l’U-46619 et la 8-isoPGE2 pouvaient agir de façon non-sélective sur l’un ou l’autre des récepteurs. Ces résultats supportent donc nos 2 premières hypothèses : les prostanoïdes font partie des molécules endogènes qui peuvent contrôler le tonus vasculaire placentaire et la prééclampsie modifie la réponse aux isoprostanes dans les artères chorioniques d’une manière compatible avec l’augmentation de la production de ces substances qui elle, est probablement le résultat du stress oxydatif. En revanche, en ce qui concerne les substances capables de jouer la contrepartie vasodilatatrice, l’utilisation d’un inhibiteur des synthases de monoxyde d’azote, le L-NAME, et celle d’inhibiteurs des COXs, l’ibuprofène, l’indométacine et le N-2PIA, ne nous a pas permis de mettre en évidence un quelconque rôle du monoxyde d’azote ou des prostanoïdes vasodilatatrices à ce niveau. Finalement, nous avons montré que l’induction d’un stress oxydatif dans les cotylédons perfusés in vitro et les artères chorioniques entraînait une vasoconstriction marquée. Celle-ci semble résulter de l’action des prostanoïdes puisqu’un blocage des récepteurs TP ou des COXs diminuait significativement la réponse maximale au peroxyde d’hydrogène. Les prostanoïdes impliquées dans la réponse au stress oxydatif proviendraient essentiellement d’une activation des COXs puisque l’étude ne nous permet pas de conclure à une quelconque implication des isoprostanes dans cette réponse. Ces observations confirment donc notre hypothèse que, dans le placenta, le stress oxydatif possède des propriétés vasoactives par activation du métabolisme de l’AA. En résumé, les résultats obtenus dans les placentas de grossesses normotensives et avec prééclampsie suggèrent que les prostanoïdes sont des molécules d’importance dans la régulation du tonus vasculaire placentaire. Le fait que la prééclampsie modifie la réponse aux prostanoïdes pourrait expliquer pourquoi la perfusion placentaire est altérée chez ces patientes. En outre, il apparaît évident qu’il existe un lien étroit entre le stress oxydatif et la voie de synthèse des prostanoïdes placentaires. Cependant d’autres études sont nécessaires pour mieux comprendre la nature de ce lien, qui pourrait, d’une certaine façon, jouer un rôle important dans le développement de la prééclampsie. / Throughout pregnancy, appropriate placental perfusion is essential for the fœtus to grow properly. In disease such as preeclampsia, placental perfusion is impaired, compromising the fœtus and mother’s lives. Placenta delivery leads to a complete disappearance of the clinical symptoms of preeclampsia. This suggests that the placenta plays a central role in the disease. Placenta being devoid of autonomous innervation, placental vascular tone needs to be under the control of humoral and tissular factors; placental arteries are very reactive to prostanoids. The thromboxane A2 (TXA2)/prostacyclin (PGI2) ratio is increased in placenta from preeclamptic women. Furthermore, in placenta from preeclamptic pregnancies, isoprostane rate is increased, which is a marker of oxidative stress. Finally, preeclampsia is characterised by an important oxidative stress. Reactive oxygen species are known to form isoprostane through the oxidation of arachidonic acid (AA) and to increase TXA2 production in various tissues following an activation of the cyclooxygenases (COXs). We postulate that: 1. prostanoids are among the endogenous molecules that control placental vascular tone. 2. preeclampsia alters responses to isoprostanes in placental vessels. 3. induced placental oxidative stress leads to vasoactive responses through the activation of the AA metabolism. We first showed in placentas from normotensive pregnancies that the TXA2 mimetic U-46619 and the isoprostane 8-isoprostaglandin E2 (8-isoPGE2) markedly increased perfusion pressure in in vitro perfused cotyledons, as well as tension in isolated chorionic arteries. However, in placentas obtained from women with preeclampsia, those responses were altered in chorionic arteries. Indeed, maximal response to U-46619 was raised by preeclampsia, while the one to 8-isoPGE2 was decreased. We then showed that preterm delivery increased maximal responses to both prostanoids compared to term delivery. This observation suggests that placental arteries reactivity evolves along the 3rd trimester of pregnancy. Nevertheless, it appeared that delivery mode had no effect on vascular responses to prostanoids, suggesting that placental prostanoids are not involved in the delivery process. The use of specific blockers of the TXA2 TP receptors, SQ29,548 and ICI192,605, and of the prostaglandin E2 EP receptors, AH6809, revealed that U-46619 and 8-isoPGE2 could mediate their effects by acting on both receptors in a non-selective manner. Therefore, these results support our two first postulates: prostanoids could be the endogenous substances controlling the placental vascular tone and preeclampsia alters responses to isoprostanes in chorionic artery rings in a way compatible with the increased production of these substances possibly through the associated oxidative stress. Moreover, we were unable to identify any vasodilator substances capable of counteracting the effects of vasoconstrictors in the placental circulation. Indeed, blocker of nitric oxide synthases, L-NAME, as well as blockers of COXs, ibuprofen, indometacin and N-2PIA, did not reveal any effect of nitric oxide and vasodilator prostanoids at this level. Finally, we showed that induction of oxidative stress in in vitro perfused cotyledons and in isolated chorionic artery rings led to marked vasoconstriction. This would result from the action of prostanoids since a blockade of TP receptors or COXs significantly decreased maximal response to hydrogen peroxide. Prostanoids involved in this response would essentially come from COX activation. Indeed, the present results did not show any concrete involvement of isoprostane substances in the response to oxidative stress. Consequently, these observations confirm our hypothesis that, in the placenta, oxidative stress presents some vasoactive properties through the activation of the AA metabolism. In summary, results obtained in placentas from normotensive and preeclamptic pregnancies suggest that prostanoids are important in the regulation of the placental vascular tone. Furthermore, responses to prostanoids in chorionic arteries are altered by preeclampsia, which could explain why the placental perfusion is impaired in the disease. Moreover, it seems clear that there is a close relationship between oxidative stress and synthesis of placental prostanoids. However, more investigations are needed to better understand the nature of this relationship, which, in some way, could play an important role in the development of preeclampsia.

Thromboxane A2 (TXA2) is an important mediator metabolized from arachidonic acid through the cyclooxygenase pathway, mainly in platelets and macrophages. It is a potent inducer of platelet aggregation and smooth muscle contraction. Its overproduction has been detected in pathologies such as stroke, asthma, myocardial infarction or atherosclerosis. The action of TXA2 is mediated by a specific G-protein coupled receptor (TP) of which two alternative spliced isoforms, TPalpha and TPbeta, have been described. The exact role of these two isoforms is not clearly understood. However, recent studies have described their implications in vascular physiology and pathology. The inhibition of the action of TXA2 on platelets and blood vessels would be interesting as original therapies against cardiovascular diseases. Consequently, the design of TP receptor antagonists remains of great interest in cardiovascular medicine. In the laboratory of medicinal chemistry (University of Liège, Belgium), several nitrobenzenesulfonylureas, derived from torasemide (a loop diuretic), have been previously described as TP receptor antagonists. Two compounds, BM573 and BM613 were among the most interesting molecules identified in that previous work. The present project is divided in two parts. First, we have determined the pharmacological properties of BM573 and BM613 as thromboxane synthase inhibitors and TP receptor antagonists, in vitro and in vivo. In our assays, these two compounds were proved to have high affinity for both TPalpha and TPbeta, to be potent antiplatelet agents, to inhibit thromboxane synthase and TP-mediated smooth muscle contraction. Additionally, they significantly reduced the size of the thrombus in a rat model of ferric chloride-induced arterial thrombosis. Consequently, we demonstrated that the TP receptor antagonists BM573 and BM613, belonging to the chemical family of nitrobenzenesulfonylureas, could be regarded as antiplatelet and antithrombotic agents potentially useful in thromboxane-related diseases such as stroke or myocardial infarction. Secondly, given the interesting pharmacological profile of BM573 and BM613, we have designed and synthesized several series of compounds derived from these two agents. We have evaluated the binding properties (affinity) of the first generation (+/- 35 original derivatives) of compounds on either TPalpha or TPbeta, transiently expressed in COS-7 cell lines. Additionally, we have measured the ability of our drugs to inhibit the intracellular calcium mobilization upon TPalpha or TPbeta stimulation. To confirm our results, we also assessed the antiplatelet properties of our drugs by means of determination of inhibition of human platelet aggregation. On the basis of the results obtained with these in vitro assays, we have synthesized and evaluated a second generation of derivatives (+/- 35 original compounds) and improved the selectivity of several original compounds for TP receptor isoforms. The originality of this work was to evaluate a large library of synthetic compounds on both TP receptor isoforms, using specific pharmacological tests. By means of structure-activity relationship studies, we were able to identify chemical groups implicated in selectivity and to propose lead compounds for development of highly specific TPalpha or TPbeta antagonists. Besides, we have identified an in vivo drug candidates for prevention of thrombosis and pathological platelet aggregation./Le thromboxane A2 (TXA2) est un métabolite de la cascade de lacide arachidonique (AA) par la voie des cyclooxygénases et de la thromboxane synthase, principalement formé dans les plaquettes et les macrophages. Le TXA2 est un puissant inducteur de lagrégation plaquettaire et de la contraction des muscles lisses vasculaires et bronchiques. Par ailleurs, une augmentation des taux en TXA2 a été constatée dans différentes pathologies : l'infarctus du myocarde, l'atherosclérose, les accidents vasculaires cérébraux, ou encore l'asthme. Laction du TXA2 sur les tissus résulte de la stimulation dun récepteur appartenant à la famille des récepteurs couplés aux protéines G. Ce récepteur au TXA2 (TP) présente deux isoformes générées par épissage alternatif, TPalpha et TPbeta. Le rôle physiologique exact de ces deux isoformes n'est pas encore connu. Cependant, de récents travaux ont mis en évidence leur importance, notamment dans la physiologie vasculaire et dans certaines pathologies. Linhibition de laction du TXA2 au niveau des plaquettes et des vaisseaux sanguins pourrait donc être une stratégie thérapeutique innovante pour traiter et prévenir les maladies cardiovasculaires. En conséquence, le développement dantagonistes des récepteurs TP reste dun grand intérêt en médecine cardiovasculaire. Des études de pharmacomodulation avaient permis au Laboratoire de Chimie Pharmaceutique (Université de Liège, Belgique) d'identifier des nitrobenzènesulfonylurées, dérivées du torasémide (un diurétique de lanse), présentant un puissant antagonisme des récepteurs TP. Parmi ceux-ci, deux composés, le BM573 et le BM613, faisaient parties des molécules les plus intéressantes identifiées au cours de ces précédentes recherches. Ce projet est divisé en deux parties. Premièrement, nous avons déterminé les propriétés pharmacologiques du BM573 et du BM613 en tant quinhibiteurs de la thromboxane synthase et antagonistes des récepteurs TP, in vitro et in vivo. Au cours de nos expériences, ces deux composés se sont révélés posséder une grande affinité pour TPalpha et TPbeta, être de puissants agents antiplaquettaires, des inhibiteurs de la thromboxane synthase et de la contraction des muscles lisses induite par le TXA2. En outre, lutilisation de ces produits dans un modèle de thrombose artérielle induite par le chlorure ferrique chez le rat a provoqué une réduction significative du thrombus formé. En conséquence, nous avons démontré que le BM573 et le BM613, appartenant à la famille chimique des nitrobenzenesulfonylurées, pouvaient être considérés comme des agents antiplaquettaires et antithrombotiques, potentiellement utiles en tant quagents thérapeutiques dans des pathologies associées au TXA2 telles que linfarctus du myocarde ou laccident vasculaire cérébral. Ensuite, nous nous sommes concentrés sur l'activité de cette famille de composés (les nitrobenzènesulfonylurées) vis-à-vis des deux isoformes du récepteur au thromboxane. Pour ce faire, nous avons conçu et synthétisé de nombreuses séries de composés dérivés du BM573 et du BM613. Nous avons tout dabord évalué laffinité de la première génération de composés (+/- 35 dérivés) sur des lignées cellulaires (COS-7) exprimant sélectivement soit TPalpha soit TPbeta. De plus, nous avons mesuré la capacité de ces composés à inhiber la mobilisation de calcium intracellulaire ([Ca2+]i) induite par la stimulation des deux isoformes TPalpha et TPbeta séparément. Nos résultats ont été confirmés sur agrégation plaquettaire humaine. Sur la base des résultats obtenus avec cette première génération de produits, nous avons synthétisé une seconde génération (+/- 35 dérivés) de composés, et avons réussi à augmenter la sélectivité en faveur de TPbeta pour certains produits. Loriginalité de ce travail réside dans le fait que nous avons évalué un nombre de produits importants sur TPalpha et TPbeta, au moyen de tests pharmacologiques spécifiques. Grâce à des études de relation structure-activité, nous avons identifié des groupements chimiques impliqués dans la sélectivité entre les deux isoformes. Nous pouvons donc proposer des structures "chef de file" pouvant être utiles pour le développement de composés hautement sélectifs, soit pour TPalpha, soit pour TPbeta. Par ailleurs, nous avons identifié in vivo des candidats pour le développement dagents thérapeutiques pour la prévention des thromboses et des autres pathologies provoquées par une activation plaquettaires excessive.